TTOO - T2 Biosystems, Inc.
| Previous Close | 5.00 |
| Open | 5.03 |
| Bid | 0.00 x 1800 |
| Ask | 0.00 x 800 |
| Day's Range | 4.50 - 5.04 |
| 52 Week Range | 3.60 - 9.98 |
| Volume | 920,958 |
| Avg. Volume | 614,703 |
| Market Cap | 207.458M |
| Beta (3Y Monthly) | 1.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.62 |
| Earnings Date | Nov 1, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.50 |
- GlobeNewswire•4 days ago
T2 Biosystems Announces 2018 Third Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., Oct. 18, 2018 -- T2 Biosystems, Inc. (Nasdaq: TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical.
- GlobeNewswire•17 days ago
T2 Biosystems Reports Granting of Inducement Awards
The inducement awards consist of options to purchase 16,500 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options is $6.82, which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on October 2, 2018.
- GlobeNewswire•19 days ago
T2 Biosystems Announces Customer Presentations at October Conferences
LEXINGTON, Mass., Oct. 03, 2018 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical.
- Motley Fool•25 days ago
Here's Why T2 Biosystems Rose as Much as 16% Today
The diagnostic innovator provided performance data for a product pipeline candidate aimed at diagnosing Lyme disease.
- GlobeNewswire•26 days ago
New Data Suggests T2 Biosystems’ T2Lyme™ Panel is More Accurate than Other Diagnostics for Identifying Borrelia Infections for Patients Suspected of Having Early Lyme Disease
T2 Biosystems, Inc. (TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today new data suggesting the T2Lyme Panel™ is more accurate than other diagnostics for identifying Borrelia infections for patients suspected of having early Lyme disease. Run on the fully automated FDA-cleared T2Dx® Instrument, the T2Lyme Panel is designed to detect Lyme disease-causing bacteria in 3 to 5 hours. The data from a 2017 pre-clinical study evaluated 21 patients enrolled with an erythema migrans (EM) rash with suspected early Lyme disease and assessed with multiple Lyme diagnostics.
- GlobeNewswire•last month
T2 Biosystems to Participate in Two Upcoming Investor Conferences
T2 Biosystems, Inc. (TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to participate in two upcoming investor conferences. The first conference is the Janney Healthcare Conference 2018, which is being held September 17-18 in New York City. This conference will allow institutional investors to meet with the Company but does not include a formal webcast presentation.
- Simply Wall St.•last month
Should T2 Biosystems Inc’s (NASDAQ:TTOO) Recent Earnings Worry You?
When T2 Biosystems Inc (NASDAQ:TTOO) released its most recent earnings update (30 June 2018), I wanted to understand how these figures stacked up against its past performance. The two benchmarksRead More...
- GlobeNewswire•last month
T2 Biosystems Reports Granting of Inducement Awards
T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of TTOO earnings conference call or presentation 2-Aug-18 8:30pm GMT
Q2 2018 T2 Biosystems Inc Earnings Call
- GlobeNewswire•3 months ago
T2 Biosystems Reports Granting of Inducement Awards
T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology.
- Associated Press•3 months ago
T2 Biosystems: 2Q Earnings Snapshot
On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 32 cents. The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- GlobeNewswire•3 months ago
T2 Biosystems Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Quarterly Product Revenue Up 71% Year-Over-Year. Launched the Recently FDA Cleared T2Bacteria Panel, the Flagship Product in the T2Direct Diagnostics Portfolio. Reiterates 2018 Financial Guidance, Including ...
- GlobeNewswire•3 months ago
T2 Biosystems to Participate in Two Upcoming Conferences
T2 Biosystems, Inc. (TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to participate in two upcoming investor conferences. This conference will allow institutional investors to meet with the Company but does not include a formal presentation. The second conference is the Canaccord Genuity 38th Annual Growth Conference, which is being held August 8-9 in Boston.
- ACCESSWIRE•4 months ago
Free Stock Performance Review on Thermo Fisher Scientific and Three Additional Medical Research Stocks
LONDON, UK / ACCESSWIRE / June 29, 2018/ If you want a free Stock Review on TMO sign up now at www.wallstequities.com/registration. Today, WallStEquities.com has selected the following Medical Laboratories and Research stocks for observation: Syneos Health Inc. (NASDAQ: SYNH), T2 Biosystems Inc. (NASDAQ: TTOO), Thermo Fisher Scientific Inc. (NYSE: TMO), and Bruker Corp. (NASDAQ: BRKR).
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of TTOO earnings conference call or presentation 8-May-18 8:30pm GMT
Q1 2018 T2 Biosystems Inc Earnings Call
- PR Newswire•5 months ago
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018
88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...
- TheStreet.com•5 months ago
How to Manage Risk in Biotech Stocks
Karl is an ex-Brooklynite who now splits time between Miami and London. The ascendancy of the Evil Empire (AKA, my beloved NY Yankees) and the fate of his miserable Mets, who look more like a M.A.S.H. unit than a baseball team for the third year in a row. Karl was quite happy with the news as he had taken my advice and loaded up on the shares in the mid-$4s several months ago and now the stock was trading near $10 on the news.
- Motley Fool•5 months ago
Here's Why T2 Biosystems, Inc. Rose Over 16% Today
The diagnostic company is rebounding after a stock offering.
